(0) items

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
Protein-protein Interactions in Drug Discovery,9783527331079
This item qualifies for

Your order must be $59 or more, you must select US Postal Service Shipping as your shipping preference, and the "Group my items into as few shipments as possible" option when you place your order.

Bulk sales, PO's, Marketplace Items, eBooks, Apparel, and DVDs not included.

Protein-protein Interactions in Drug Discovery



by ; ; ; ;
Pub. Date:
List Price: $210.00

Buy New Textbook

Usually Ships in 3-4 Business Days

Rent Textbook

We're Sorry
Sold Out

Used Textbook

We're Sorry
Sold Out


We're Sorry
Not Available

More New and Used
from Private Sellers
Starting at $170.72

Questions About This Book?

What version or edition is this?

This is the 1st edition with a publication date of 3/4/2013.

What is included with this book?

  • The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any CDs, lab manuals, study guides, etc.


Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the development pipeline of major pharmaceutical companies to illustrate the power and potential of this approach.

Author Biography

Alexander D?mling studied Chemistry and Biology at the Technical University Munich, Germany. After obtaining his PhD under the supervision of Ivar Ugi, he spent a postdoctoral year at the Scripps Research Institute in La Jolla (USA) in the group of Nobel Laureate Barry Sharpless. In 2004 he performed his habilitation at the Technical University of Munich. Since 2006 he is associate professor at the University of Pittsburgh in the Department of Pharmacy with secondary appointments in Chemistry and Computational Biology. Dr. D?mling is founder of several biotech companies, including Morphochem and R&D Biopharmaceuticals. His research centers around the discovery of antagonists of protein-protein interactions in the therapeutic areas of oncology, infectious and neglected tropical diseases.

Table of Contents

Protein-Protein Interactions: An Overview
Prediction of intra- and inter-species protein-protein interactions facilitating systems biology studies
Modulators of protein-protein interactions: The importance of Three-Dimensionality
A leap into the chemical space of Protein-Protein Interaction inhibitors
Interactive technologies for leveraging the known chemistry of anchor residues to disrupt protein interactions
SH3 Domains as Drug Targets
P53 MDM2 Antagonists: Towards Non Genotoxic Anticancer Treatments
Inhibition of LFA-1/ICAM interaction for treatment of autoimmune diseases
The PIF-binding pocket of AGC kinases: a target site for allosteric modulators and protein-protein interaction inhibitors
Retosiban and Epelsiban: Potent and Selective Orally available Oxytocin Antagonists
Peptidic inhibitors of protein-protein interactions for cell adhesion receptors: RGD peptides and beyond
The REPLACE Strategy for generating Non-ATP competitive Inhibitors of Cell-Cycle Protein Kinases

Please wait while the item is added to your cart...